慢性炎症疾患に対するIL-23抑制

Vipul Jairath¹, Maria Laura Acosta Felquer², Raymond Jaihyun Cho³

¹Departments of Medicine, Division of Gastroenterology, Western University, Ontario, ON, Canada.

Lancet (London, England)

|October 26, 2024

まとめ

インタールイキン (IL-23) 阻害剤は,牛皮病や炎症性腸疾患などの慢性炎症疾患の有効な治療法です. IL- 23p19を標的とした治療は,他の治療法と比較して優れた効果と安全性を示しています.

科学分野:

免疫学
薬理学について
皮膚科

背景:

モノクローナル抗体は,慢性炎症性疾患におけるサイトカインシグナル伝達を標的とする.
インタールイキン (IL) - 23 阻害剤は,牛皮病や炎症性腸疾患の治療に不可欠です.
これらの阻害剤は共通の病理的メカニズムに対応し,高い有効性と持続的な反応を提供します.

研究の目的:

IL - 23 阻害剤の有効性と安全性を検討する.
p40とp19サブユニットを標的にするIL-23阻害剤を比較する.
IL - 23 阻害剤の有効性における抗体の親和性の役割を評価する.

主な方法:

IL - 23 阻害剤の臨床試験データを集約した分析.
IL-23阻害剤と腫瘍死滅因子α阻害剤の有効性の比較
蓄積された長期安全性データの見直し

主要な成果:

IL - 23 阻害剤は高い有効性を示し,牛皮病患者の70%以上,IBD 患者の50%までが改善を示した.
IL-23独特のp19タンパク質を標的とする阻害剤は,プラーク型牛皮病におけるTNFα阻害剤よりも優れた有効性を示しています.
IL - 23 阻害剤の重篤な有害事象および感染率はプラセボと比較できます.

結論:

IL - 23 阻害剤,特にp19 阻害剤は,牛皮病および炎症性腸疾患の治療における重要な進歩を表しています.
効能は抗体親和によって調節され,さらなる調査が必要である.
これらの治療法は,承認された指示において好ましい安全性プロファイルを提供します.

さらに関連する動画

12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

34.4K

10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

8.8K

関連する概念動画

01:24

T Cell Types and Functions

955

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

955

01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

117

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

117

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

143

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

143

01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

01:28

Inflammatory Response

1.9K

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

1.9K

01:17

Drugs Used in Lower Respiratory Disorders: Overview

353

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

353

関連する実験動画